<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37904690</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Examining the relationship between inflammatory biomarkers during COVID-19 hospitalization and subsequent long-COVID symptoms: A longitudinal and retrospective study.</ArticleTitle><Pagination><StartPage>e1052</StartPage><MedlinePgn>e1052</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.1052</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Long-COVID is a heterogeneous condition with a litany of physical and neuropsychiatric presentations and its pathophysiology remains unclear. Little is known about the association between inflammatory biomarkers, such as interleukin-6 (IL-6) and C-reactive protein (CRP) in the acute phase, and persistent symptoms after hospitalization in COVID-19 patients.</AbstractText><AbstractText Label="METHODS">IL-6, CRP, troponin-T, and ferritin were analyzed at admission for all patients with COVID-19 between September 1, 2020 to January 10, 2021. Survivors were followed up 3-months following hospital discharge and were asked to report persistent symptoms they experienced. Admission data were retrospectively collected. Independent t-tests and Mann-Whitney U tests were performed.</AbstractText><AbstractText Label="RESULTS">In a sample of 144 patients (62.5% male, mean Age 62 years [SD&#x2009;=&#x2009;13.6]) followed up 3 months after hospital discharge, the commonest symptoms reported were fatigue (54.2%), breathlessness (52.8%), and sleep disturbance (37.5%). In this sample, admission levels of IL-6, CRP and ferritin were elevated. However, those reporting myalgia, low mood, and anxiety at follow-up had lower admission levels of IL-6 (34.9 vs. 52.0&#x2009;pg/mL, p&#x2009;=&#x2009;.043), CRP (83 vs. 105&#x2009;mg/L, p&#x2009;=&#x2009;.048), and ferritin (357 vs. 568&#x2009;ug/L, p&#x2009;=&#x2009;.01) respectively, compared with those who did not report these symptoms. Multivariate regression analysis showed that these associations were confounded by gender, as female patients had significantly lower levels of IL-6 and ferritin on admission (29.5 vs. 56.1, p&#x2009;=&#x2009;.03 and 421.5 vs. 589, p&#x2009;=&#x2009;.001, respectively) and were more likely to report myalgia, low mood and anxiety, when compared to males.</AbstractText><AbstractText Label="CONCLUSIONS">Our data demonstrate that female patients present more often with lower levels of inflammatory biomarkers on admission which are subsequently associated with long-term post-COVID symptoms, such as myalgia and anxiety, in those discharged from hospital with severe COVID-19. Further research is needed into the role of serum biomarkers in post-COVID prognostication.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sykes</LastName><ForeName>Dominic L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Hull York Medical School, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van der Feltz-Cornelis</LastName><ForeName>Christina M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0001-6925-8956</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences, University of York, York, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hull York Medical School, York, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Sciences, University College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holdsworth</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Buckinghamshire Healthcare NHS Trust, Aylesbury, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Simon P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Hull York Medical School, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Halloran</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHS Frimley Health Foundation Trust, Frimley, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holding</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hull York Medical School, Hull, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crooks</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Hull York Medical School, Hull, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">interleukin-6</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>3</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37904690</ArticleId><ArticleId IdType="pmc">PMC10614127</ArticleId><ArticleId IdType="doi">10.1002/iid3.1052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID&#x2010;19: a meta&#x2010;analysis. Int J Infect Dis. 2020;96:467&#x2010;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233226</ArticleId><ArticleId IdType="pubmed">32425643</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2010;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco&#x2010;Melo D, Nilsson&#x2010;Payant BE, Liu WC, et al. Imbalanced host response to SARS&#x2010;CoV&#x2010;2 drives development of COVID&#x2010;19. Cell. 2020;181(5):1036&#x2010;1045. 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiers N. Recognising and bearing the burden of long COVID&#x2010;related disability. Br J Gen Pract. 2022;72(715):70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8813105</ArticleId><ArticleId IdType="pubmed">35091402</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post&#x2010;COVID&#x2010;19 symptom burden: what is long&#x2010;COVID and how should we manage it? Lung. 2021;199(2):113&#x2010;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. Physical, cognitive, and mental health impacts of COVID&#x2010;19 after hospitalisation (PHOSP&#x2010;COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021;9(11):1275&#x2010;1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, Leavy OC, Richardson M, et al. Clinical characteristics with inflammation profiling of long COVID and association with 1&#x2010;year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761&#x2010;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal&#x2010;Zegarra D, Paredes&#x2010;Angeles R, Mayo&#x2010;Puchoc N, Vilela&#x2010;Estada AL, Huarcaya&#x2010;Victoria J, Copez&#x2010;Lonzoy A. An explanatory model of depressive symptoms from anxiety, post&#x2010;traumatic stress, somatic symptoms and symptom perception: The role of inflammatory markers in hospitalized COVID&#x2010;19 patients. BMC Psych. 2022;22(1):638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9548421</ArticleId><ArticleId IdType="pubmed">36210450</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Feltz&#x2010;Cornelis C, Brabyn S, Ratcliff J, et al. Assessment of cytokines, microRNA and patient related outcome measures in conversion disorder/functional neurological disorder (CD/FND): the CANDO clinical feasibility study. Brain Behav Immunity Health. 2021;13:100228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474571</ArticleId><ArticleId IdType="pubmed">34589743</ArticleId></ArticleIdList></Reference><Reference><Citation>Heseltine&#x2010;Carp W, Dale V, van der Sluijs JvE, van der Feltz&#x2010;Cornelis C. Are serum hsCRP and IL&#x2010;6 prognostic markers in somatic symptom disorder and related disorders? An exploratory analysis in a prospective cohort study. J Psychiatr Res. 2023;157:88&#x2010;95. 10.1016/j.jpsychires.2022.11.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.11.026</ArticleId><ArticleId IdType="pubmed">36455378</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitton R, Sweetman J, Heseltine&#x2010;Carp W, van der Feltz&#x2010;Cornelis C. Anti&#x2010;inflammatory medications for the treatment of mental disorders: a scoping review. Brain Behav Immun Health. 2022;26:100518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9547233</ArticleId><ArticleId IdType="pubmed">36217374</ArticleId></ArticleIdList></Reference><Reference><Citation>Badenoch JB, Rengasamy ER, Watson C, et al. Persistent neuropsychiatric symptoms after COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Brain Commun. 2021;4(1):fcab297. 10.1093/braincomms/fcab297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab297</ArticleId><ArticleId IdType="pmc">PMC8833580</ArticleId><ArticleId IdType="pubmed">35169700</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L, Kannapadi NV, Briggs J, et al. Mid and long&#x2010;term neurological and neuropsychiatric manifestations of post&#x2010;COVID&#x2010;19 syndrome: a meta&#x2010;analysis. J Neurol Sci. 2022;434:120162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed&#x2010;Hussein AAR, Amin MT, Makhlouf HA, et al. Non&#x2010;hospitalised COVID&#x2010;19 patients have more frequent long COVID&#x2010;19 symptoms. Int J Tuberc Lung Dis. 2021;25(9):732&#x2010;737.</Citation><ArticleIdList><ArticleId IdType="pubmed">34802495</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaes AW, Go&#xeb;rtz YMJ, Van Herck M, et al. Recovery from COVID&#x2010;19: a sprint or marathon? 6&#x2010;month follow&#x2010;up data from online long COVID&#x2010;19 support group members. ERJ Open Res. 2021;7(2):00141&#x2010;02021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012818</ArticleId><ArticleId IdType="pubmed">34041295</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Ryan&#x2010;Murua P, Rodr&#xed;guez&#x2010;Jim&#xe9;nez J, Palacios&#x2010;Ce&#xf1;a M, Arendt&#x2010;Nielsen L, Torres&#x2010;Macho J. Serological biomarkers at hospital admission are not related to long&#x2010;term post&#x2010;COVID fatigue and dyspnea in COVID&#x2010;19 survivors. Respiration. 2022;101:658&#x2010;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9148886</ArticleId><ArticleId IdType="pubmed">35381597</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS&#x2010;CoV&#x2010;2 infection is common and independent of severity of initial infection. PLoS One. 2020;15(11):e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46&#x2010;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919277</ArticleId><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud K. Stressful life events and major depression. Clin Sci Insights. 2010;14:1&#x2010;4.</Citation></Reference><Reference><Citation>Liu YZ, Wang YX, Jiang CL. Inflammation: the common pathway of stress&#x2010;related diseases. Front Hum Neurosci. 2017;11:316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5476783</ArticleId><ArticleId IdType="pubmed">28676747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohleder N. Stimulation of systemic low&#x2010;grade inflammation by psychosocial stress. Psychosom Med. 2014;76(3):181&#x2010;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">24608036</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcia MA, Bonsall DR, Bloomfield PS, Selvaraj S, Barichello T, Howes OD. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology. 2016;233:1637&#x2010;1650.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828495</ArticleId><ArticleId IdType="pubmed">26847047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellavance M, Rivest S. The HPA&#x2013;immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front Immunol. 2014;5:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3978367</ArticleId><ArticleId IdType="pubmed">24744759</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Feltz&#x2010;Cornelis CM, Sweetman J, Allsopp G, et al. STIMULATE&#x2010;ICP&#x2010;Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long&#x2010;COVID to Address and Transform Existing Integrated Care Pathways Delphi): study protocol. PLoS One. 2022;17(11):e0277936. 10.1371/journal.pone.0277936</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0277936</ArticleId><ArticleId IdType="pmc">PMC9710789</ArticleId><ArticleId IdType="pubmed">36449461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>